96 related articles for article (PubMed ID: 8175027)
21. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between serum CA125 level and prognosis in the patients with uterine endometrial carcinoma].
Xie Z; Zhang J; Tan A
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(23):1456-7. PubMed ID: 11930622
[TBL] [Abstract][Full Text] [Related]
23. High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review.
Ghaemmaghami F; Karimi Zarchi M; Hamedi B
Arch Gynecol Obstet; 2007 Nov; 276(5):559-61. PubMed ID: 17497163
[TBL] [Abstract][Full Text] [Related]
24. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
27. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
28. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
29. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Keys HM; Roberts JA; Brunetto VL; Zaino RJ; Spirtos NM; Bloss JD; Pearlman A; Maiman MA; Bell JG;
Gynecol Oncol; 2004 Mar; 92(3):744-51. PubMed ID: 14984936
[TBL] [Abstract][Full Text] [Related]
30. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
31. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
32. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
Barakat RR; Bundy BN; Spirtos NM; Bell J; Mannel RS;
J Clin Oncol; 2006 Feb; 24(4):587-92. PubMed ID: 16446331
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
34. [Serum CA125 measurement is useful in 3 cases with pericardial effusion].
Toshihiko S; Megumi U; Takahiro H; Keizo K; Chikao K; Tsunenori T; Katsuya K; Hiroki F; Mitsuko H
Kokyu To Junkan; 1993 Apr; 41(4):389-92. PubMed ID: 8516579
[TBL] [Abstract][Full Text] [Related]
35. Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
Ramirez PT; Slomovitz BM; Soliman PT; Coleman RL; Levenback C
Gynecol Oncol; 2006 Aug; 102(2):252-5. PubMed ID: 16472844
[TBL] [Abstract][Full Text] [Related]
36. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
[TBL] [Abstract][Full Text] [Related]
37. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
38. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
[TBL] [Abstract][Full Text] [Related]
39. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
[TBL] [Abstract][Full Text] [Related]
40. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
